Natco Pharma is currently trading at Rs. 821.15, up by 2.65 points or 0.32% from its previous closing of Rs. 818.50 on the BSE.

The scrip opened at Rs. 818.50 and has touched a high and low of Rs. 826.85 and Rs. 818.05 respectively. So far 4192 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 928.45 on 07-Sep-2023 and a 52 week low of Rs. 502.00 on 02-Feb-2023.

Last one week high and low of the scrip stood at Rs. 861.90 and Rs. 816.85 respectively. The current market cap of the company is Rs. 14660.14 crore.

The promoters holding in the company stood at 49.71%, while Institutions and Non-Institutions held 24.97% and 25.32% respectively.

Natco Pharma has invested around $2 million in Cellogen Therapeutics to support development of affordable cell and gene therapies in India. Cellogen is primarily involved in two R&D programs involving cell and gene therapy solutions. Chimeric Antigen Receptor T (CAR T) cell therapy program is at an advanced stage for Cellogen Therapeutics where the T cells of the patients are genetically engineered to identify and kill the cancer cells. 

Cellogen Therapeutics has developed bi-specific CARs and also added another costimulatory domain to increase the efficacy and persistence of the CAR in human body as compared to currently available CAR constructs that are mono-specific with one co-stimulatory domain. Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy which remains a major challenge with existing CAR constructs. Current available products in market cost around $500,000 - 700,000 which Cellogen aims to bring down to $60,000 - 70,000.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.